Accelerating Discovery Into
Translational Medicine
500+
Active Trials
1,200+
Validated Biomarkers
Bench
To Bedside Pipeline
Patient
Centered Outcomes
Trans·la·
tion·al Med·i·cine
/ trænzˈleɪʃənəl ˈmedəsən / · noun
noun · applied clinical scienceAn interdisciplinary framework that converts laboratory and preclinical discovery into validated clinical application - moving findings bidirectionally between bench and bedside to accelerate biomarker validation, therapeutic design, and evidence-based patient care.
Origin
From Latin translatio (a carrying across) + medicina (the healing art). Translational medicine emerged in the late 20th century as the NIH and academic medical centers formalized the "T1–T4" continuum, recognizing that scientific discovery only becomes healthcare impact once it survives the journey from mechanism, to model, to trial, to practice.
The Translational Medicine Department at the American Board of Precision Medicine trains clinicians to bridge the gap between emerging science and everyday practice - applying biomarker discovery, preclinical modeling, and rigorous trial design to move promising research into interventions that actually reach patients.
From target validation and preclinical models to adaptive clinical trial design, regulatory science, and precision therapeutics, this department equips physicians with the scientific and operational fluency to carry a discovery across every stage of the translational continuum - without it stalling before it can help someone.
Discovery alone changes nothing for a patient until it is translated. At ABOPM, Translational Medicine provides the bench-to-bedside framework to carry mechanism into evidence and evidence into practice, so that research findings become real, patient-centered outcomes.
500+
Active Trials
1.2K+
Validated Biomarkers
T1–T4
Translational Continuum
Where Discovery at the Bench
Becomes Healing at the Bedside
The Translational Medicine Department at ABOPM is redefining how scientific discovery reaches the patient — training physicians to move findings from molecular research and clinical trials into real-world practice, integrating biomarker validation, trial design literacy, and bench-to-bedside frameworks into clinical strategies that accelerate the safe, evidence-based delivery of precision therapies to every individual patient.
Advancing clinical application of biomarker discovery, mechanistic validation, and preclinical-to-clinical bridging enabling physicians to interpret emerging research and translate laboratory findings into actionable, individualized treatment decisions.
Building board-certified frameworks for critical appraisal of trial methodology, adaptive and biomarker-driven trial design, and regulatory pathway navigation to accelerate the responsible adoption of emerging precision therapeutics.
Building the next generation of translational medicine physicians through rigorous board standards, evidence-synthesis training, and interdisciplinary collaboration across clinical research, biostatistics, regulatory science, and precision diagnostics.
"Every breakthrough in the lab is only as valuable as its journey to the patient. The Translational Medicine Department at ABOPM trains physicians to make that journey — turning biomarker science and clinical trial evidence into precision care that reaches the bedside faster and safer."
American Board of Precision Medicine · Translational Medicine DepartmentCarrying Discovery Across the Gap
to Deliver Evidence-Ready Patient Care
No discovery heals a patient until it crosses the gap. Behind every promising biomarker and every landmark trial lies a translational pipeline - preclinical validation, trial design, regulatory review, and real-world implementation - that conventional clinical training was never designed to navigate. Carrying evidence safely and rigorously from bench to bedside is not a research specialty on the sidelines - it is the systems-level obligation of modern precision medicine.
Translational medicine equips clinicians to move beyond passive consumption of published literature and into active stewardship of the evidence pipeline - applying biomarker validation, critical trial appraisal, and regulatory pathway literacy to determine which findings are ready for the clinic, which require further scrutiny, and how emerging therapeutics reach the individual patient faster and safer.
By mastering translational medicine, clinicians gain the power to:
Why Translational Medicine Certification Is Non-Negotiable
Every discovery has a translational path. The question is, are you equipped to carry it?
Translationally-informed clinical strategies consistently move validated discoveries into practice faster than reactive, literature-lagging approaches delivering measurably earlier patient access to therapies that have genuinely cleared the evidentiary bar.
Adaptive trial designs, companion diagnostics, and real-world evidence platforms are transforming how therapeutics reach patients - physicians board-certified in translational medicine will define the next generation of evidence-driven, precision-guided care.
Board certification in translational medicine marks you as the evidence-translation authority - a physician equipped to lead biomarker validation programs, trial design review, and regulatory strategy development at the institutional level.
Translational medicine principles apply universally across oncology, cardiology, neurology, immunology, and metabolic disease giving you a disease-agnostic evidence framework to evaluate and implement emerging therapeutics across every specialty and patient population.
Active research areas driving translational medicine forward:
The translational medicine revolution is not a future event - it is rewriting how quickly and how safely discovery reaches the patient today. Biomarker qualification, adaptive trial design, real-world evidence integration, and companion diagnostic co-development are actively transforming how every precision therapeutic is validated, approved, and delivered at the individual patient level.
The ABOPM Translational Medicine Department positions clinicians at the center of this transformation equipping them with the evidence-appraisal literacy, regulatory science frameworks, and board-certified credentials to lead evidence-driven precision medicine across every disease domain and patient population.
Meet Our Leadership
— Chair of Translational Medicine —
Ali Asadi, PhD, MSc, MBA
Ali Asadi serves as the Chief Innovation Officer of TAM Global, bringing strategic leadership and scientific expertise to the forefront of biotechnology. As Chair of Translational Medicine with the American Board of Precision Medicine, he plays a pivotal role in guiding the clinical integration of advanced multi-omics and next-generation therapeutics.
With a Ph.D. in Organic Chemistry from the University of British Columbia and an MBA, he built a career as a Principal Investigator bridging academia and industry. At The Scripps Research Institute, his NIH-supported research produced some of the first prototypes for nanopore sequencing, and he later held pivotal scientific and leadership roles at Illumina.
Read full bio
A prolific inventor and serial entrepreneur, Dr. Asadi has co-founded multiple biotech ventures focused on oligonucleotide therapeutics and precision medicine. He manages a robust intellectual property portfolio, with numerous patents and trade secrets across diagnostics, oncology, genomics, and proteomics. He spearheaded the first nationwide neonatal disease screening program in Iran, invented the foundational chemistry behind the first FDA-approved pan-cancer diagnostic assay profiling more than 500 oncology genes, and helped develop a groundbreaking 10,000-plex proteomics panel in collaboration with SomaLogic and Illumina.
Today he leads a dedicated team of scientists at TAM Global, working with a network of international partners on the integration of advanced multi-omics, next-generation cancer therapeutics, and neurodegenerative conditions. He is focused on novel molecular diagnostics for rare diseases, including autism spectrum disorder (ASD), and on advanced targeted modalities, spanning peptide, oligonucleotide, and stem cell therapies, with the goal of treating and potentially curing addressable subtypes of highly refractory diseases.
His commitment to health and longevity extends to veterinary science. A devoted animal lover and active dog rescuer, he has spearheaded molecular and diagnostic innovations focused on canine health, expanding the frontiers of veterinary precision medicine.
Above all, Dr. Asadi's work is fueled by a humanitarian passion: translating complex bench science into accessible clinical solutions and working to make transformative precision care a universal reality for all.
Faculty Members
Our faculty roster is growing — announcements coming soon.
Faculty position open
Faculty position open
Faculty position open
Faculty position open
Think you're the right fit for a faculty position?
Get Involved →
Shaping the Future
of Precision Medicine
As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.
The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.
Insights Shaping
Precision Medicine
Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.
Eight Advances in Precision Medicine: What Clinicians Need to Know
Explore eight advances in precision medicine, from rapid genomic sequencing and targeted cancer therapies to gene therapy, and discover what these breakthroughs mean for clinical practice. ...more
On the Frontier
October 22, 2026•10 min read
Digital Biomarkers and Wearable Health Data
Explore how digital biomarkers and wearable technologies are enabling continuous health monitoring, early disease detection, and more personalized approaches to precision medicine. ...more
On the Frontier
October 15, 2026•8 min read
From Lab Report to Treatment Plan: Interpreting Molecular Diagnostics
Explore how clinicians interpret molecular diagnostic reports and translate genomic, transcriptomic, and proteomic findings into informed, personalized treatment decisions. ...more
Precision Medicine in Action
October 08, 2026•8 min read
Stay at the Forefront of Precision Medicine
Subscribe to receive ABOPM insights, research updates, and educational resources delivered directly to your inbox.
Advancing education, certification, and leadership to shape a genomics-driven, data-intelligent future of healthcare.
COMPANY
RESOURCES
© 2023-2025 American Board of Precision Medicine, Inc. All Rights Reserved.